REDWOOD CITY, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of…
EG427 Announces New Preclinical Results from Multiple Studies of EG110A in Neurogenic Detrusor Overactivity (NDO) and Overactive Bladder (OAB) In…
MINNEAPOLIS & WASHINGTON--(BUSINESS WIRE)--Vensana Capital, a leading medical technology-focused venture capital and growth equity investment firm, today announced the promotions…
VANCOUVER, British Columbia, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that…
MENLO PARK, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the…
Trial Meets Both Primary and Key Secondary EndpointsLAVAL, QC / ACCESSWIRE / December 21, 2023 / Bausch Health Companies Inc.…
PALO ALTO, Calif., and RESEARCH TRIANGLE PARK, N.C., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Kriya Therapeutics, Inc. ("Kriya"), a biopharmaceutical…
CAMBRIDGE, Mass., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the European Commission has revoked…
NEW YORK, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage…
~ Patients treated with AMT-130 continue to show evidence of preserved neurological function with potential dose-dependent clinical benefits relative to…